Genexis Group’s net sales Q4 2024 were EUR 16.9 million, EUR 1.6 million higher than Q4 2023. Order intake was EUR 24.2 million, EUR 1.2 million above Q4 2023.
The consolidated adjusted EBITDA of Q4 2024 was EUR 1.6 million (EUR 0.7 million Q4 2023), and the operating cash flow after investment activities in Q4 2024 was negative by EUR -1.2 million.
“Our order intake is increasing steadily, but slowly. We continue to sign on new customers, but it takes considerable time before this materializes in increase in revenue. At the same time, the market continues to be slow in our core areas” says Genexis Group CEO Gerlas van den Hoven. “Market conditions are still on the slow side and revenue in Q4 2024 was stable at similar levels shown throughout the year.”
“Our order intake is increasing steadily, but slowly. We continue to sign on new customers, but it takes considerable time before this materializes in increase in revenue. At the same time, the market continues to be slow in our core areas” says Genexis Group CEO Gerlas van den Hoven. “Market conditions are still on the slow side and revenue in Q4 2024 was stable at similar levels shown throughout the year.”
You can find the complete report at https://genexis.eu/investors/#financial
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO U.S. PERSONS OR IN OR INTO ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL.
For further information, please contact:
Magnus Björnum, CFO, Genexis Group
Tel: +46 707 100 208
E-mail: magnus.bjornum@genexis.eu
